贫血仍然是一个普遍的全球健康问题,其严重程度各不相同。静脉补铁,特别是羧基麦芽糖铁(FCM),已作为中度至重度贫血患者的一种可能的治疗干预措施。该研究旨在评估羧基麦芽糖铁(FCM)减少贫血的有效性和安全性。
■我们搜索了电子数据库,登记册,网站,电子图书馆,评论的参考列表,引文,等。我们纳入了随机对照试验(RCTs),非RCT,和单臂研究,而观察性研究,案例系列,案例研究被排除在外。两名评审员独立筛选研究并提取数据。我们纳入了中度至重度贫血印度人的研究,并排除了患有其他合并症的印度人。我们使用GDT等级评估偏倚风险和总体证据质量(QoE)。
■我们确定了255项研究,包括14项研究(11项随机对照试验,一个非RCT,和两项单臂研究),1,972名参与者进行定性分析,10项研究进行荟萃分析。所有纳入的研究都详细介绍了FCM在贫血中的应用。纳入研究评估的主要结局是贫血,血红蛋白,和不良事件。评估的结果范围为2周至12周。偏倚的风险在不同研究中具有不同的结果。与其他干预措施相比,FCM与较少数量的不良事件一致,并提供“中等”至“非常低”的QoE。
■单次缓慢输注1克FCM耐受性良好,安全,有效治疗缺铁性贫血(IDA),并超越其他干预措施(蔗糖铁复合物(ISC),蔗糖铁,和抗坏血酸亚铁)提高血红蛋白水平和补充铁储备。
■https://www.crd.约克。AC.uk/prospro/display_record.php?RecordID=459363,CRD42023459363。
UNASSIGNED: Anemia remains a prevalent global health issue with varying severity. Intravenous iron supplementation, particularly with ferric carboxymaltose (FCM), has appeared as a possible therapeutic intervention for individuals with moderate to severe anemia. The study aimed to assess the efficacy and safety of ferric carboxymaltose (FCM) in reducing anemia.
UNASSIGNED: We searched electronic databases, registries, websites, e-libraries, reference lists of reviews, citations, etc. We included randomized control trials (RCTs), non-RCTs, and single-arm studies, while observational studies, case series, and case studies were excluded. Two reviewers independently screened the studies and extracted the data. We included studies of moderate-to-severely anemic Indians and excluded Indians with other comorbidities. We assessed the risk of bias and the overall quality of evidence (QoE) using GRADE GDT.
UNASSIGNED: We identified 255 studies and included 14 studies (11 RCT, one non-RCT, and two single-arm studies) with 1,972 participants for qualitative analysis and 10 studies in the meta-analysis. All the included studies detailed the use of FCM for anemia. The primary outcomes assessed in the included studies were anemia, hemoglobin, and adverse events. The outcomes assessed ranged from 2 weeks to 12 weeks. The risk of bias varied across different studies with different outcomes. FCM is consistent with a fewer number of adverse events as compared to other interventions and provides \"moderate\" to \"very low\" QoE.
UNASSIGNED: A slow single infusion of 1 gram of FCM is well-tolerated, safe, and effective in treating iron deficiency anemia (IDA) and surpasses other interventions (Iron Sucrose Complex (ISC), Iron sucrose, and ferrous ascorbate) in elevating hemoglobin levels and replenishing iron stores.
UNASSIGNED: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=459363, CRD42023459363.